Clinical Trials
5
Active:0
Completed:2
Trial Phases
1 Phases
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 4
3 (100.0%)Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Claudio Gobbi
- Target Recruit Count
- 45
- Registration Number
- NCT04640818
- Locations
- 🇨🇭
Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Ticino, Switzerland
Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Claudio Gobbi
- Target Recruit Count
- 93
- Registration Number
- NCT02082002
- Locations
- 🇨🇭
Ospedale Regionale di Lugano - Civico, Lugano, Ticino, Switzerland
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Phase 4
Terminated
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Claudio Gobbi
- Target Recruit Count
- 5
- Registration Number
- NCT01701856
- Locations
- 🇨🇭
Ospedale Regionale di Lugano - Civico, Lugano, Ticino, Switzerland
Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Claudio Gobbi
- Target Recruit Count
- 27
- Registration Number
- NCT01411514
- Locations
- 🇨🇭
Osepdale Civico, Lugano, Ticino, Switzerland
Natalizumab De-escalation With Interferon Beta-1b
Phase 4
Completed
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Claudio Gobbi
- Target Recruit Count
- 19
- Registration Number
- NCT01144052
- Locations
- 🇨🇭
Neurocenter of Southern Switzerland, Ospedale Civico Lugano, Lugano, Ticino, Switzerland
News
No news found